|
|
|
|
Treatment with interferon beta-1a did not significantly affect disability progression in this cohort, although significant treatment benefit was observed on exacerbation-related outcomes. Exploratory post hoc analyses suggested greater bene fit in women and in patients who had reported at least one relapse in the 2 years before the study. |
|